REZUROCK (Belumosudil) Sales Forecast and Market Size Analysis 2020-2025 & 2026-2034

Opportunities include deeper uptake in refractory chronic GvHD, expansion across Europe and Asia, broader pediatric access through an oral suspension, and potential use in lung transplant rejection and other fibrotic or immune-mediated diseases.

Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "REZUROCK Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

REZUROCK (belumosudil) continues to strengthen its position in the chronic graft-versus-host disease (cGvHD) treatment market, supported by increasing physician adoption, international expansion and growing clinical experience. Sanofi's oral, selective ROCK2 inhibitor is approved for eligible patients with cGvHD following failure of prior systemic therapies, with specific labeling varying by market.

Key Factors Driving REZUROCK Market Growth

• Established role in chronic GvHD: REZUROCK addresses inflammatory and fibrotic pathways associated with cGvHD. Its differentiated clinical profile and increasing use in refractory disease have supported its adoption across launched markets.
• Strong commercial performance: According to Sanofi's 2025 Annual Report, global REZUROCK sales reached €490 million in 2025, increasing 8.7% at constant exchange rates compared with 2024. United States sales totaled €425 million, while international growth benefited from uptake in markets including China.
• Expanding geographic reach: By the end of 2025, REZUROCK had received approval in 20 countries, with launches across the United States, China, Japan, South Korea, Thailand, Canada and the United Kingdom, among other markets.
• Clinical differentiation: Results from the pivotal Phase II ROCKstar trial demonstrated responses across multiple affected organs, durable clinical Benefit and meaningful symptom improvement. Once-daily oral administration and a generally manageable safety profile also support treatment adoption.
• Lifecycle development opportunities: Sanofi is evaluating additional formulations and indications, including an oral suspension intended to support pediatric use and the Phase III ROCKaspire study in chronic lung allograft dysfunction following bilateral lung transplantation.

More than 20,000 patients worldwide have received REZUROCK through commercial availability, early-access initiatives or managed-access programs since launch. Continued reimbursement gains, broader physician familiarity and entry into additional markets are expected to remain important components of the product's future commercial performance.

Recent REZUROCK Regulatory Development

In March 2026, the European Commission granted conditional marketing authorization for REZUROCK for the treatment of chronic GvHD in adults and adolescents aged 12 years and older who weigh at least 40 kg. The authorization applies when other treatment options offer limited clinical Benefit , are unsuitable or have been exhausted. Continued authorization is subject to the completion of a confirmatory randomized controlled study.

REZUROCK Drug and Clinical Development Summary

REZUROCK selectively inhibits ROCK2 and modulates immune and profibrotic signaling implicated in chronic GvHD. The therapy was originally developed by Kadmon, which is now part of Sanofi. Clinical evidence from the ROCKstar program and subsequent real-world use has reinforced its role as a targeted treatment for eligible patients with refractory cGvHD.

Sanofi is also assessing the potential of belumosudil in additional immune-mediated and fibrotic disorders. The Phase III ROCKaspire trial is evaluating its use in chronic lung allograft dysfunction after bilateral lung transplantation. However, the Phase III ROCKnrol-1 study in newly diagnosed chronic GvHD was discontinued following a futility analysis. Future growth will therefore depend partly on the outcomes of ongoing development programs, regulatory decisions and competitive conditions.

Scope of the REZUROCK Market Report

The "REZUROCK Sales Forecast and Market Size Analysis-2034" report provides a comprehensive assessment of the product's historical performance, current market position and forecast commercial outlook. It evaluates chronic GvHD and selected potential opportunities, including chronic lung allograft dysfunction, idiopathic pulmonary fibrosis, systemic sclerosis, autoimmune disorders and multiple myeloma.

The analysis covers the seven major pharmaceutical markets: the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. It includes historical and forecast REZUROCK sales from 2020 through 2034, subject to the report's underlying assumptions and scenario analysis.

• REZUROCK market size, sales trends and revenue forecasts through 2034
• Mechanism of Action , dosage, administration and product profile
• Clinical trials, development status and anticipated study milestones
• Regulatory approvals, market launches and geographic expansion
• Pricing, reimbursement, treatment costs and regional variations
• Patent landscape, potential generic entry and associated pricing impact
• Competitive positioning and late-stage pipeline analysis
• SWOT analysis and independent analyst perspectives
• Commercial partnerships, licensing transactions and relevant M&A activity

REZUROCK Competitive Landscape and Revenue Potential

The report assesses marketed therapies and emerging products that may affect REZUROCK market share. Competitive analysis examines clinical differentiation, safety and efficacy, route of administration, pricing, reimbursement access and expected launch timelines. It also considers how late-stage therapies could influence prescription patterns and future sales across approved and potential indications.

REZUROCK's long-term revenue potential is expected to be shaped by sustained use in chronic GvHD, additional regulatory approvals, reimbursement expansion and successful development in new indications. Market barriers include intensifying competition, clinical development risk, regional access constraints and the potential long-term effect of patent expiry or generic entry.

Strategic Value of the Report

The report supports pharmaceutical companies, investors, consultants and healthcare stakeholders seeking to understand the REZUROCK market outlook. Its assessment of sales forecasts, clinical milestones, pricing trends, competitors and pipeline developments can inform portfolio planning, market-entry strategy, investment evaluation and commercial decision-making within the immunology, transplantation and fibrotic disease sectors.

Key Topics Covered

1. Report Introduction

2. REZUROCK Overview in approved indications like Graft-versus-host disease and Lung transplant rejection; as well as potential indication like Idiopathic pulmonary fibrosis, Systemic scleroderma, Autoimmune disorders, and Multiple myeloma
2.1. Product Detail
2.2. REZUROCK Clinical Development
2.2.1. REZUROCK Clinical studies
2.2.2. REZUROCK Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile

3. REZUROCK Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging REZUROCK Therapies)

5. REZUROCK Market Assessment
5.1. REZUROCK Market Outlook in approved and potential indications
5.2. 7MM Analysis
5.2.1. REZUROCK Market Size in the 7MM for approved and potential indications
5.3. Country-wise Market Analysis
5.3.1. REZUROCK Market Size in the United States for approved and potential indications
5.3.2. REZUROCK Market Size in Germany for approved and potential indications
5.3.3. REZUROCK Market Size in France for approved and potential indications
5.3.4. REZUROCK Market Size in Italy for approved and potential indications
5.3.5. REZUROCK Market Size in Spain for approved and potential indications
5.3.6. REZUROCK Market Size in the United Kingdom for approved and potential indications
5.3.7. REZUROCK Market Size in Japan for approved and potential indications

6. REZUROCK SWOT Analysis

7. Analyst's Views

8. Appendix
8.1. Bibliography
8.2. Report Methodology

List of Tables
Table 1: REZUROCK, Clinical Trial Description, 2023
Table 2: REZUROCK, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: REZUROCK's pricing and cost Assumptions
Table 6: REZUROCK's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: REZUROCK Market Size in the US, in USD million (2020-2034)
Table 8: REZUROCK Market Size in Germany, in USD million (2020-2034)
Table 9: REZUROCK Market Size in France, in USD million (2020-2034)
Table 10: REZUROCK Market Size in Italy, in USD million (2020-2034)
Table 11: REZUROCK Market Size in Spain, in USD million (2020-2034)
Table 12: REZUROCK Market Size in the UK, in USD million (2020-2034)
Table 13: REZUROCK Market Size in Japan, in USD million (2020-2034)

List of Figures
Figure 1: REZUROCK's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: REZUROCK Market Size in the United States, USD million (2020-2034)
Figure 3: REZUROCK Market Size in Germany, USD million (2020-2034)
Figure 4: REZUROCK Market Size in France, USD million (2020-2034)
Figure 5: REZUROCK Market Size in Italy, USD million (2020-2034)
Figure 6: REZUROCK Market Size in Spain, USD million (2020-2034)
Figure 7: REZUROCK Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: REZUROCK Market Size in Japan, USD million (2020-2034)

For more information about this report visit https://www.researchandmarkets.com/r/8ka6xp

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900